MethylGene Inc.

MethylGene Inc.

June 05, 2006 08:00 ET

MethylGene's, HDAC Inhibitor, MGCD0103 Selected as a Leading Cancer Project by Windhover Survey

MONTREAL, QUEBEC--(CCNMatthews - June 5, 2006) - MethylGene Inc. (TSX:MYG) today announced that Donald F. Corcoran, President and Chief Executive Officer of MethylGene, will present at Windhover's Therapeutics Alliance Oncology Conference in Atlanta at 12:10 p.m., ET on Wednesday, June 7, 2006.

Mr. Corcoran will discuss MethylGene's MGCD0103, which was selected by Windhover as one of the ten leading cancer projects. MGCD0103's selection is based on results from a survey that polled leading U.S. oncologists for their opinions on the most interesting projects currently in development for the treatment of cancer. The survey was performed by Clinical Advisors, an independent research firm, on behalf of Windhover.

MGCD0103, an oral, isotype-selective histone deacetylase (HDAC) inhibitor, is currently in Phase I trials for solid tumors and hematological malignancies, and in a Phase I/II trial in combination with Vidaza® (azacitidine, marketed by Pharmion Corp.), for hematological malignancies. The Company expects to embark on an additional Phase I/II combination trial during the second quarter of 2006 and two monotherapy trials during the second half of 2006.

"We are honored to have been chosen as one of the top ten leading cancer projects in the Windhover survey and the distinction is even more significant since it is based on the opinions of leading oncologists throughout the U.S. - those in pursuit of the latest cutting edge technologies for the care and treatment of cancer patients," said Mr. Corcoran.

About MethylGene

MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases. We intend to exploit our HDAC inhibitor technology in diseases other than cancer, such as diabetes, inflammation, fungal infections and neurodegenerative disorders. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Pharmion Corporation and Taiho Pharmaceutical Co., Ltd., and MG98, partnered with MGI Pharma, Inc. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has partnered its non-oncology HDAC program for neurodegenerative diseases with EnVivo Pharmaceuticals. MethylGene has a portfolio of preclinical programs for its multi-targeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and continues to seek partnering opportunities in these areas. Please visit our website at

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, which you are urged to read, as described in MethylGene's Annual Information Form for the fiscal year ending December 31, 2005, under the heading "risk factors," that can be found at Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

Contact Information

  • MethylGene Inc.
    Andrea Gilpin, Ph.D, MBA
    Director, Investor Relations
    (514) 337-3333 ext. 416